Annual Reports

 
Quarterly Reports

 
8-K

  • 8-K (Nov 8, 2013)
  • 8-K (Oct 29, 2013)
  • 8-K (Oct 22, 2013)
  • 8-K (Oct 2, 2013)
  • 8-K (Sep 27, 2013)
  • 8-K (Sep 11, 2013)

 
Other

Allergan Finance LLC 8-K 2010

Documents found in this filing:

  1. 8-K
  2. Ex-1.1
  3. Ex-5.1
  4. Ex-5.1
e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 11, 2010
WATSON PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Its Charter)
 
         
Nevada   001-13305   95-3872914
(State or Other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification No.)
     
311 Bonnie Circle    
Corona, California   92880
(Address of Principal Executive Offices)   (Zip Code)
Registrant’s telephone number, including area code: (951) 493-5300
(Former name or former address, if changed since last report): Not applicable.
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 


TABLE OF CONTENTS

Item 8.01. Other Events
Item 9.01. Financial Statements and Exhibits
SIGNATURE
EXHIBIT INDEX
EX-1.1
EX-5.1


Table of Contents

Item 8.01. Other Events.
     On November 11, 2010, Watson Pharmaceuticals, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC (the “Underwriter”) and Quiver Inc., a British Virgin Islands limited liability company and a stockholder of the Company (the “Selling Stockholder”), pursuant to which the Selling Stockholder agreed to sell to the Underwriter 10,537,755 shares of common stock, par value $0.0033 per share of the Company at a price of $49.58 per share. A copy of the Underwriting Agreement is attached hereto as Exhibit 1.1 and is incorporated herein by reference. The offering closed on November 17, 2010. The Company will not receive any of the proceeds from this offering.
     The offering was registered under an effective Registration Statement on Form S-3 (Registration No. 333-161404) and a related prospectus supplement, each filed with the Securities and Exchange Commission. The descriptions of the Underwriting Agreement in this report is a summary and is qualified in its entirety by the terms of the Underwriting Agreement.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
     
Exhibit No.   Description
1.1
  Underwriting Agreement by and among the Company, Quiver Inc. and J.P. Morgan Securities LLC, dated November 11, 2010.
 
   
5.1
  Opinion of Greenberg Traurig, LLP, dated November 17, 2010.
 
   
23.1
  Consent of Greenberg Traurig, LLP (included in Exhibit 5.1)

 


Table of Contents

SIGNATURE
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
Date: November 17, 2010  WATSON PHARMACEUTICALS, INC.
 
 
  By:   /s/ David A. Buchen    
    Name:   David A. Buchen   
    Title:   Senior Vice President,
General Counsel and Secretary 
 
 

 


Table of Contents

EXHIBIT INDEX
     
Exhibit No.   Description
1.1
  Underwriting Agreement by and among the Company, Quiver Inc. and J.P. Morgan Securities LLC, dated November 11, 2010
 
   
5.1
  Opinion of Greenberg Traurig, LLP, dated November 17, 2010
 
   
23.1
  Consent of Greenberg Traurig, LLP (included in Exhibit 5.1)

 

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki